Prior guidance was $175M-$185M. Cuts FY23 adjusted EBITDA view to ($85M) to ($80M) from ($75M) to ($65M).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NSTG:
- NSTG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NanoString price target lowered to $8 from $14 at Morgan Stanley
- 10x Genomics: UPC declines to issue second injunction against NanoString
- NanoString sees Q3 revenue ‘over’ $48M, consensus $46.26M
- NanoString and partners establish joint lab for spatial genomics in Singapore